Skip to Content
Top

Immunotherapy, which stimulates the patient’s own immune system to attack cancer, has shown promise in treating a variety of cancer types with long-term responses. This class of therapy involves a range of treatments, including checkpoint blockade inhibitors, vaccines and cell-based therapies.

MD Anderson’s adoptive-cell therapy (ACT) platform, which supports the Moon Shots Program™ was established to develop promising new...

BY Lany Kimmons

For their role in transforming cancer care, three MD Anderson faculty received the American Society of Clinical Oncology’s Special Awards...

BY Laura Sussman

Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared...

BY Laura Sussman

In recent years, five new immunotherapy drugs have been approved to treat patients diagnosed with urinary cancer. But the drugs, which held promise for replacing standard chemotherapy treatment, shrank tumors in only 15 to 20 percent of patients.

An international Phase II trial led by MD Anderson researchers may provide an alternative. The trial showed that treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated...

BY Laura Sussman

In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of women...

BY Clayton R. Boldt, Ph.D.

Understanding evolution within cancer cells is a longtime interest for Nicholas Navin, Ph.D., an associate professor of Genetics and Bioinformatics...

BY Laura Sussman

In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved...

BY Sarah Watson

Eight MD Anderson researchers have been selected as the newest class of Andrew Sabin Family Fellows. As part of the Andrew Sabin Family Fellowship...

BY Michael Hardy

Shortly after arriving at MD Anderson in 1987 as a junior faculty member, Guillermina Lozano, Ph.D., attended several seminars hosted by the...

BY Payal Pandit Talati, MPH

Reducing the incidence of melanoma through primary and secondary prevention is among one of the shared goals and key partnership strategies...